Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.93
- Piotroski Score 5.00
- Grade Buy
- Symbol (SPRO)
- Company Spero Therapeutics, Inc.
- Price $1.25
- Changes Percentage (-3.13%)
- Change -$0.04
- Day Low $1.25
- Day High $1.26
- Year High $1.89
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
- Last Earnings 08/07/2015
- Ex-Dividend for 5/16 Dividend 09/16/2015
- Dividend Payable 10/07/2015
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.44
- Trailing P/E Ratio 3.19
- Forward P/E Ratio 3.19
- P/E Growth 3.19
- Net Income $22.81 M
Income Statement
Quarterly
Annual
Latest News of SPRO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
'Jeopardy!' viewers hit out at mispronunciation ruling -- "I call foul"
Jeopardy! contestant faces challenge for mispronouncing "Weimaraner" as "Weimareiner." Fans debate over host Ken Jennings' ruling as incorrect. Despite this, contestant Will Wallace emerges as the win...
By Newsweek | 1 week ago -
Why mispronunciations like 'Eye-ran' matter
During the vice presidential debate, both candidates mispronounced "Iran" as "Eye-ran" instead of "Ee-rahn." This mispronunciation, whether intentional or accidental, can have significant implications...
By The Hill | 1 week ago -
Hated Brussels sprouts as a kid? Maybe this will change your mind.
To incorporate more vegetables into your meals, try cooking Brussels sprouts correctly for a tasty and nutritious option. Seasonal produce like pumpkin, squash, apples, and Brussels sprouts are fresh,...
By USA Today | 2 weeks ago
